In May 2018, the Biograph Vision PET/CT system was installed at the University Medical Center Groningen. This study evaluated the initial experiences with this new PET/CT system in terms of perceived image quality and semiquantitative analysis in comparison to the Biograph mCT as a reference. Methods: In total, 20 oncologic patients were enrolled and received a single 3 MBq/kg injected dose of 18F-FDG followed by a dual-imaging PET scan. Ten patients were scanned on the Biograph mCT first, whereas the other 10 patients were scanned on the Biograph Vision first. The locally preferred clinically reconstructed images were blindly reviewed by 3 nuclear medicine physicians and scored (using a Likert scale of 1-5) on tumor lesion demarcation, overall image quality, and image noise. In addition, these clinically reconstructed images were used for semiquantitative analysis by measurement of SUVs in tumor lesions. Images acquired using reconstructions conform with the European Association of Nuclear Medicine Research Ltd. (EARL) specifications were also used for measurements of SUV in tumor lesions and healthy tissues for comparison between systems. Results: The 18F-FDG dose received by the 14 men and 6 women (age range, 36-84; mean ± SD, 61 ± 16 y) ranged from 145 to 405 MBq (mean ± SD, 268 ± 59.3). Images acquired on the Biograph Vision were scored significantly higher on tumor lesion demarcation, overall image quality, and image noise than images acquired on the Biograph mCT (P < 0.001). The overall interreader agreement showed a Fleiss κ of 0.61 (95% confidence interval, 0.53-0.70). Furthermore, the SUVs in tumor lesions and healthy tissues agreed well (within 95%) between PET/CT systems, particularly when EARL-compliant reconstructions were used on both systems. Conclusion: In this initial study, the Biograph Vision showed improved image quality compared with the Biograph mCT in terms of lesion demarcation, overall image quality, and visually assessed signal-to-noise ratio. The 2 systems are comparable in semiquantitatively assessed image biomarkers in both healthy tissues and tumor lesions. Improved quantitative performance may, however, be feasible using the clinically optimized reconstruction settings.

中文翻译：

---

Biograph Vision PET / CT系统上的图像质量和半定量测量：初步经验和与Biograph mCT的比较。

2018年5月，在格罗宁根大学医学中心安装了Biograph Vision PET / CT系统。这项研究相对于Biograph mCT作为参考，评估了这种新型PET / CT系统在感知图像质量和半定量分析方面的初步经验。方法：总共招募了20名肿瘤患者，并接受了单剂量3 MBq / kg的18F-FDG注射剂量，然后进行了双成像PET扫描。首先在Biograph mCT上扫描了10位患者，而其他10位在Biograph Vision上首先扫描了患者。由3名核医学医师对本地首选的临床重建图像进行盲目检查，并对肿瘤病变范围，总体图像质量和图像噪声进行评分（使用1-5的李克特量表）。此外，通过测量肿瘤病变中的SUV，将这些临床重建的图像用于半定量分析。使用重建获得的图像符合欧洲核医学研究协会（EARL）规范，还用于测量肿瘤病变和健康组织中的SUV，以进行系统之间的比较。结果：14名男性和6名女性（年龄范围36-84；平均值±SD，61±16 y）接受的18F-FDG剂量为145至405 MBq（平均值±SD，268±59.3）。在Biograph Vision上获得的图像在肿瘤病变分界，整体图像质量和图像噪声方面得分均比在Biograph mCT上获得的图像得分高（P <0.001）。阅读者之间的总体协议显示Fleissκ为0.61（95％置信区间0.53-0.70）。此外，PET / CT系统之间的肿瘤病变和健康组织中的SUV吻合良好（在95％以内），特别是在两个系统上都使用EARL兼容的重建体时。结论：在这项初步研究中，相比于Biograph mCT，Biograph Vision在病变界限，整体图像质量和视觉评估的信噪比方面显示出更高的图像质量。在健康组织和肿瘤病变中，这两个系统在半定量评估图像生物标志物中具有可比性。但是，使用临床优化的重建设置可以提高定量性能。与Biograph mCT相比，Biograph Vision在病变分界，整体图像质量和视觉评估的信噪比方面显示出更高的图像质量。在健康组织和肿瘤病变中，这两个系统在半定量评估图像生物标志物中具有可比性。但是，使用临床优化的重建设置可以提高定量性能。与Biograph mCT相比，Biograph Vision在病变分界，整体图像质量和视觉评估的信噪比方面显示出更高的图像质量。在健康组织和肿瘤病变中，这两个系统在半定量评估图像生物标志物中具有可比性。但是，使用临床优化的重建设置可以提高定量性能。